IGM Biosciences Inc. (IGMS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

IGM Biosciences Inc. (IGMS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.72

-0.05 (-3.10%)

At close: Jan 14, 2025, 3:59 PM

1.71

-0.52%

Pre-market Jan 15, 2025, 06:13 AM EST

undefined% (undefined)

Bid	1.71
Market Cap	102.22M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.07
PE Ratio (ttm)	-0.56
Forward PE	n/a
Analyst	Hold

Ask	1.85
Volume	750,637
Avg. Volume (20D)	346,883
Open	1.78
Previous Close	1.77
Day's Range	1.65 - 1.81
52-Week Range	1.65 - 22.50
Beta	undefined

About IGMS

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinica...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 18, 2019

Employees 198

Stock Exchange NASDAQ

Ticker Symbol IGMS

Website https://igmbio.com

Analyst Forecast

According to 8 analyst ratings, the average rating for IGMS stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 16.35% from the latest price.

Buy 12.50%

Hold 87.50%

Sell 0.00%

Stock Forecasts

Next Earnings Release

IGM Biosciences Inc. is scheduled to release its earnings on Mar 6, 2025, during market hours.
Analysts project revenue of $270.00K, reflecting a -58.53% YoY shrinking and earnings per share of -0.79, making a -21.78% decrease YoY.

Why Price Moved

5 days ago · Source

-66.29%

IGM Biosciences shares are trading lower after the... Unlock content with Pro Subscription

1 month ago · Source

+8.99%

IGM Biosciences shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating on the stock and announced a price target of $21.

News

6 days ago · https://thefly.com

IGM Biosciences downgraded to Hold from Buy at Stifel

Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th firm cites the company's "surprising decision" to discontinue all further development of its autoimmu...

6 days ago · https://thefly.com

IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences to Underweight from Equal Weight with a price target of $2, down from $12. The company announced discontinuation of its autoimmune program...

5 days ago · https://thefly.com

IGM Biosciences downgraded to Market Perform from Outperform at BMO Capital

BMO Capital downgraded IGM Biosciences to Market Perform from Outperform with a price target of $2, down from $21, following the company's strategic update, which included discontinuation of imvotamab...

5 days ago · marketwatch.com

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

2 months ago · zacks.com

IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.04 per share a year ago.